Critical Pharmacodynamic Warning
acalabrutinib affects the 3A457 metabolic pathway.
When patients take acalabrutinib concurrently with drugs metabolized by 3A457, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.
Clinical Impact: As a strong inhibitor , acalabrutinib can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.
Clinical Overview for acalabrutinib
This page outlines known interaction pathways involving acalabrutinib, focusing primarily on its profile as a Strong inhibitor affecting the 3A457 pathway.
Enzyme Interaction Profile
acalabrutinib demonstrates strong inhibitor potency against 3A457. Clinical significance of this interaction requires further evaluation.
Inhibitor
A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.
Clinical Example: acalabrutinib affects 3A457Inducer
A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.
Interaction Details
| Drug Name | acalabrutinib |
| Affected Enzyme | 3A457 |
| Inhibitor Strength | Strong inhibitor Unknown |
| Inducers | No inducers listed |
| Inhibitors | mibefradil |
Clinical Recommendations
Consult primary literature for guidance.
- Therapeutic drug levels
- Adverse effect monitoring
- Clinical response assessment
- Consider dose reduction
- Evaluate alternative therapies
- Adjust based on response
Quick Facts
7746
3A457
Enzyme Inhibition
Unknown
Clinical Significance
Clinical significance requires further evaluation.
Information Sources
- FDA Drug Interaction Database
- Clinical Pharmacology Guidelines
- Pharmaceutical Labeling Information
- Published Clinical Studies
Last updated: June 11, 2026